La vendita allo scoperto per Dermata Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Dermata Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Dermata Therapeutics (NASDAQ:DRMA) Azioni, Report sulle vendite allo scoperto

Dermata Therapeutics

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

WIIM

AISP

ARQQ

CFLT

DOCU

LPSN

MANH

MNDY

NICE

NTRP

PCOR

RDZN

SMSI

UPLD

ZENA

Shares of semiconductor stocks are trading higher, with stocks broadly rising amid a drop in yields. President-elect Trump nominated Scott Bessent as Treasury Secretary.

<a href="https://x.com/Zevia/status/1861122204433252406" title="https://x.com/Zevia/status/1861122204433252406">https://x.com/Zevia/status/1861122204433252406</a>

News

ZVIA

Watching Shares Of Zevia; Company Posts On X, "Find us at @walmart NATIONWIDE with 10 naturally delicious flavors, plus our exclusive Walmart new Variety 8 Pack!"

<a href="https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/" title="https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/">https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/</a>

Trading Ideas

'Cleveland-Cliffs CEO still keen on acquiring U.S. Steel as uncertainty weighs on Nippon bid' - The Globe And Mail

Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.73, a high estimate of $60.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 6.29% from the previous average price target of $47.73.
<img src="https://www.benzinga.com/files/images/story/2024/1732561279_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Summit Materials by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Heurta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.50</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$52.50</td>
<td>$54.00</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Adrian Heurta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Summit Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Summit Materials compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Summit Materials's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Summit Materials's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Summit Materials analyst ratings.</a>
<h2>Discovering Summit Materials: A Closer Look</h2>
Summit Materials Inc is engaged in the production and sale of aggregates, cement, ready-mix concrete, asphalt paving mix and concrete products and owns and operates quarries, sand and gravel pits, two cement plants, cement distribution terminals, ready-mix concrete plants, asphalt plants and landfill sites. It is also engaged in paving and related services. The Company's three operating and reporting segments are the West, East and Cement segments. It operates in 21 U.S. states and in British Columbia, Canada and has assets in 21 U.S. states and in British Columbia, Canada through its platform.
<h3>Key Indicators: Summit Materials's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Summit Materials's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 47.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Summit Materials's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Summit Materials's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Summit Materials's debt-to-equity ratio stands notably higher than the industry average, reaching 0.65. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Summit Materials Stock: Analyst Perspectives (11 Ratings)

Throughout the last three months, 27 analysts have evaluated Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $245.7, a high estimate of $300.00, and a low estimate of $184.00. This upward trend is evident, with the current average reflecting a 1.34% increase from the previous average price target of $242.46.
<img src="https://www.benzinga.com/files/images/story/2024/1732561266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Apple is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Hold</td>
<td>$215.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$184.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$262.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Kyle Mcnealy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$212.92</td>
<td>$205.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$186.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Pierre Ferragu</td>
<td>New Street Research</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Hold</td>
<td>$203.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$261.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$236.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$295.00</td>
<td>$245.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apple. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apple compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apple's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Apple's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apple analyst ratings.</a>
<h2>All You Need to Know About Apple</h2>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Key Indicators: Apple's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Apple's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.07% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apple's ROE excels beyond industry benchmarks, reaching 23.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Apple's ROA stands out, surpassing industry averages. With an impressive ROA of 4.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Apple's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

What 27 Analyst Ratings Have To Say About Apple

Throughout the last three months, 4 analysts have evaluated Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $3.0, a high estimate of $4.00, and a low estimate of $2.00. Marking an increase of 9.09%, the current average surpasses the previous average price target of $2.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1732561247_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rigetti Computing. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rigetti Computing. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Rigetti Computing's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Rigetti Computing's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rigetti Computing analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Rigetti Computing</h2>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
<h3>Rigetti Computing: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Rigetti Computing's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -23.41%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Rigetti Computing's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -623.76%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Rigetti Computing's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.11%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Rigetti Computing's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.28%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.18.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGTI

Analyst Scoreboard: 4 Ratings For Rigetti Computing

Throughout the last three months, 47 analysts have evaluated Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">22</td>
<td align="right">21</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">13</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $654.6, with a high estimate of $811.00 and a low estimate of $525.00. Witnessing a positive shift, the current average has risen by 7.76% from the previous average price target of $607.47.
<img src="https://www.benzinga.com/files/images/story/2024/1732561232_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Meta Platforms. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$641.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$705.00</td>
<td>$645.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$719.00</td>
<td>$690.00</td>
</tr>
<tr>
<td>Aaron Kessler</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$675.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$660.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$635.00</td>
<td>$620.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$630.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$583.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$660.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$675.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$660.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$530.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$650.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$630.00</td>
<td>$605.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$811.00</td>
<td>$811.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$650.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$670.00</td>
<td>$670.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$636.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$663.00</td>
<td>$590.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$620.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$585.00</td>
<td>-</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$650.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$650.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$670.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$655.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$525.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$690.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$665.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$652.00</td>
<td>$647.00</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$780.00</td>
<td>-</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$660.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Raises</td>
<td>Buy</td>
<td>$620.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$811.00</td>
<td>$643.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$630.00</td>
<td>$563.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$640.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$635.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$605.00</td>
<td>$530.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$660.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$645.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$600.00</td>
<td>-</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$660.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Meta Platforms. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Meta Platforms compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Meta Platforms's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/META/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Meta Platforms analyst ratings.</a>
<h2>Discovering Meta Platforms: A Closer Look</h2>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
<h3>A Deep Dive into Meta Platforms's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Meta Platforms showcased positive performance, achieving a revenue growth rate of 18.87% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Meta Platforms's net margin is impressive, surpassing industry averages. With a net margin of 38.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Meta Platforms's ROE stands out, surpassing industry averages. With an impressive ROE of 9.77%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Meta Platforms's ROA stands out, surpassing industry averages. With an impressive ROA of 6.45%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.3, Meta Platforms adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Meta Platforms Through 47 Analysts

Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.
Analysts estimate that Best Buy Co will report an earnings per share (EPS) of $1.29. 
Anticipation surrounds Best Buy Co's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.18 in the last quarter, leading to a 0.22% increase in the share price on the following day.
Here's a look at Best Buy Co's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.16</td>
<td>1.08</td>
<td>2.51</td>
<td>1.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.34</td>
<td>1.20</td>
<td>2.72</td>
<td>1.29</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>4.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732561223_0.png" alt="eps graph" />
<h3>Best Buy Co Share Price Analysis</h3>
Shares of Best Buy Co were trading at $89.54 as of November 22. Over the last 52-week period, shares are up 30.91%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Best Buy Co</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Best Buy Co.
A total of 17 analyst ratings have been received for Best Buy Co, with the consensus rating being Buy. The average one-year price target stands at $106.65, suggesting a potential 19.11% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and GameStop, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Underperform trajectory for GameStop, with an average 1-year price target of $10.0, implying a potential 88.83% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for and GameStop are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best Buy Co</td>
<td>Buy</td>
<td>-3.08%</td>
<td>$2.19B</td>
<td>9.40%</td>
</tr>
<tr>
<td>GameStop</td>
<td>Underperform</td>
<td>-31.41%</td>
<td>$248.80M</td>
<td>0.52%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Best Buy Co has a higher consensus rating compared to its peer. It has a positive revenue growth rate, while its peer has a negative growth rate. Best Buy Co also has a higher gross profit margin. Additionally, Best Buy Co has a significantly higher return on equity compared to its peer. Overall, Best Buy Co outperforms its peer across all key metrics analyzed.
<h3>All You Need to Know About Best Buy Co</h3>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Best Buy Co faced challenges, resulting in a decline of approximately -3.08% in revenue growth as of 31 July, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Best Buy Co's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.4%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Best Buy Co's ROA excels beyond industry benchmarks, reaching 1.92%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.32, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/BBY/earnings">To track all earnings releases for Best Buy Co visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Preview For Best Buy Co

NetApp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NYSE">NTAP</a>) short percent of float has risen 19.62% since its last report. The company recently reported that it has 8.89 million shares sold short, which is 5.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>NetApp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732561223_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NetApp has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing NetApp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, NetApp's peer group average for short interest as a percentage of float is 6.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NTAP

Peering Into NetApp's Recent Short Interest

FS KKR Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) short percent of float has fallen 18.92% since its last report. The company recently reported that it has 3.35 million shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>FS KKR Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732561217_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for FS KKR Capital has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing FS KKR Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, FS KKR Capital's peer group average for short interest as a percentage of float is 3.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into FS KKR Capital's Recent Short Interest

Ally Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) short percent of float has fallen 4.41% since its last report. The company recently reported that it has 7.90 million shares sold short, which is 2.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ally Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732561212_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ally Financial has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ally Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ally Financial's peer group average for short interest as a percentage of float is 7.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ALLY

Peering Into Ally Financial's Recent Short Interest

<a href="https://www.benzinga.com/personal-finance/24/09/40972049/dave-ramsey-tells-29-year-old-1m-in-debt-and-spending-like-shes-in-congress-im-getting-ready-to-">Dave Ramsey's</a> live radio show is no stranger to strong opinions, but Chris from Los Angeles took things up a notch. From the very start, Chris didn't hold back. "You've done some great work and in some ways, I love you, but in other ways, you're stupid and arrogant," he declared. Ramsey's co-host Ken Coleman couldn't help but note, "That's a great way to start a conversation," with a sarcastic edge.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Chris, undeterred, went straight for the jugular. "Are you smarter than Warren Buffett?" he asked, challenging Ramsey's long-standing advice on actively managed funds. Clearly not in the mood for hypotheticals, Ramsey cut him off: "Let's stop for a second – what's the point of your call?"
Chris explained that the point was to call out Ramsey for recommending actively managed mutual funds over index funds. According to Chris, investors could end up with 50% more money at retirement if they stick with low-cost index funds instead of paying higher fees for actively managed ones.
Ramsey wasn't buying it. "Not sure where you went to school for your math class, but you failed," he shot back. With decades of experience under his belt, Ramsey insisted that his picks for actively managed funds have consistently outperformed the indexes. "I've got socks older than you," he quipped, doubling down on his claim that, with proper research, it's possible to find actively managed funds that deliver better returns.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a>
When Chris mentioned Warren Buffett's endorsement of index funds, Ramsey pointed out that <a href="https://www.benzinga.com/startups/24/09/41028012/warren-buffett-bet-1m-he-could-outperform-hedge-funds-over-a-decade-he-did-it-with-a-strategy-requir">Buffett himself doesn't stick solely to passive investing</a>. "He actually has an actively managed portfolio called Berkshire Hathaway," Ramsey said. "I really don't have a problem with index funds. You can get rich with index funds – but not 50% richer. That's complete BS."
As the call spiraled into a back-and-forth, Ramsey clarified his position: he practices what he preaches. "I've been doing this for 30 years and it's made me a multi-multi-multi-millionaire," he said. "I invest in the same actively managed growth stock mutual funds I tell people to use."
By the end of the exchange, Ramsey couldn't resist one final jab. "I think we're confused as to who's arrogant on this call, brother," he said, before recommending Chris read How to Win Friends and Influence People.&nbsp;
<h2 class="wp-block-heading">So, Is Ramsey Right?</h2>
The <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">debate between active and passive investing</a> isn't new and both sides have their merits. Index funds often appeal to investors because of their low fees and simplicity.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
Studies show that many actively managed funds fail to outperform their benchmarks over time. Visual Capitalist reports that over 20 years, 95% of large-cap actively managed funds have underperformed their benchmark. However, Ramsey's point about selecting high-performing funds is valid – though it requires more effort and expertise than many investors are willing to put in.
So, who's right here? It depends on your priorities. For hands-off investors, index funds might be the way to go. But for those willing to do their homework – or hire someone who will – actively managed funds could offer a <a href="https://www.benzinga.com/personal-finance/24/08/40318568/mark-cuban-says-to-get-rich-invest-10-of-savings-in-high-risk-investments-but-if-its-bitcoin-thr">chance to beat the market</a>.
One thing's for sure – Ramsey doesn't shy away from a challenge. Whether you agree with his advice or not, his conviction is hard to ignore. As for Chris, maybe next time he'll work on his delivery. "You're stupid and arrogant" isn't exactly the best opener.&nbsp;
<a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">Consulting a financial advisor</a> can be a smart move if you're deciding on the best investment strategy for your needs. They can walk you through your options, breakdown the pros and cons and help design a plan tailored to your goals.
Read Next:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Personal Finance

Caller Asks Dave Ramsey 'Are You Smarter Than Warren Buffett?' As He Claims Index Funds Outperform Actively Managed Funds by 50%

Following a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984522/dogwifhat-up-70-in-7-days-can-its-coinbase-listing-trigger-a-shiba-inu-like-1800-rally">listing on Coinbase</a>, Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) has been listed for trading by Robinhood Crypto.
What Happened: The company <a href="https://x.com/RobinhoodApp/status/1861039611742683635">announced</a> the listing on its X account on Monday. WIF has underperformed its bigger rivals over the past week.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>&nbsp;$3.21</td>
<td>$3.2 Billion</td>
<td>&nbsp;+3.6%</td>
<td>&nbsp;-7.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.4039</td>
<td>$59.3 Billion</td>
<td>&nbsp;-2.6%</td>
<td>&nbsp;+8%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002579&nbsp;&nbsp;</td>
<td>$15.2 Billion</td>
<td>&nbsp;+3.6%</td>
<td>&nbsp;+3.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Altcoin Sherpa highlighted the underperformance of Dogwifhat compared to Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>), attributing part of it to low unit bias, which may limit broader interest. Despite this, Sherpa <a href="https://x.com/AltcoinSherpa/status/1861054913041576291">remains</a> optimistic about Dogwifhat&#8217;s potential upside.
Crypto trader Murad <a href="https://x.com/MustStopMurad/status/1861050662764605471">called</a> the Robinhood listing a major win for meme coins, predicting that the &#8220;meme coin supercycle will last much longer than people expect.&#8221;
Trader Free <a href="https://x.com/free_electron0/status/1861033210047590715">wondered</a> if Dogwifhat might follow the trajectory of Dogecoin and Shiba Inu, whose Robinhood listings triggered significant rallies. 
Trader Davie Satoshi shared a bullish prediction, forecasting Dogwifhat to rise between $5 and $10, potentially reaching an all-time high in December or January
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Rapid Fire Charts: <a href="https://twitter.com/search?q=%24WIF&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$WIF</a> Just a holding pattern here to set up for the next leg up. Expecting all time highs in Dec/Jan and <a href="https://twitter.com/search?q=%24WIF&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$WIF</a> to approach $5-10 <a href="https://t.co/lAxF4PxESp">pic.twitter.com/lAxF4PxESp</a>
&mdash; davie satoshi (@NFTdavie) <a href="https://twitter.com/NFTdavie/status/1861044003199717841?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader DonAlt remarked, &#8220;Meme coins are tired,&#8221; suggesting the sector needs fresh interest to drive another pump.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Memecoins are tired Need lots of new people to come in to pump these or they&#39;ll start rotting away <a href="https://t.co/TEfqMOZ78c">https://t.co/TEfqMOZ78c</a> <a href="https://t.co/GvV7qNEthP">pic.twitter.com/GvV7qNEthP</a>
&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1861040784968999195?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984522/dogwifhat-up-70-in-7-days-can-its-coinbase-listing-trigger-a-shiba-inu-like-1800-rally">Dogwifhat Up 70% In 7 Days Can Its Coinbase Listing Trigger A Shiba Inu-Like 1,800% Rally?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BONK

$DOGE

$SHIB

$WIF

Dogwifhat Now Available To Trade On Robinhood — Can That Stop Its Underperformance Against Dogecoin, Shiba Inu?

<a href="https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/">https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/</a>
The Drug Enforcement Administration (DEA) and the prohibitionist group Smart Approaches to Marijuana (SAM) have categorically denied allegations that they illegally conspired together during the Biden administration's marijuana rescheduling process.
In a response to a motion seeking to remove DEA from the rescheduling proceedings over alleged ex parte communications with SAM, the agency on Monday said it "unequivocally denies" the charge and requested a dismissal of the motion from Hemp for Victory and Village Farms International.
"Movants' own evidence fails to demonstrate that any unlawful ex parte communication took place," DEA said in its brief with the administrative law judge (ALJ) overseeing the case. "The Movants would have this tribunal embark on a fishing expedition in search of evidence to support these sweeping, unsupported claims, which at best can be categorized as gossip, not ex parte communications."
The original filing included screenshots of social media posts where the group's president, Kevin Sabet, indicated he had private conversations with DEA officials about the rescheduling effort as SAM rallied opposition to the reform and urged the agency to keep marijuana in Schedule I.
One week prior to DOJ's publication of the proposed rule, Sabet posted on X that he could confirm DEA Administrator Anne Milgram wouldn't sign the notice, citing "two confidential sources inside DEA and another outside DEA with intimate knowledge."
The agency said that doesn't amount to ex parte communications, however.
"The tribunal correctly questions the seriousness of the remedies sought by the Movants and as such, should deny the motion," it said in the new filing, referring to comments from the judge last week. DEA added that the cannabis organizations behind the motion failed to "identify any precedent that would support removing an agency from its own rulemaking process."
"The only authority cited by the Movants on this point simply supports the notion that specific individuals may be removed from the proceeding under the appropriate circumstances," it said, pointing out that there is no accusation of any wrongdoing by DEA attorneys involved in the current proceedings on rescheduling. "In short, the Movants' arguments are completely without merit."
SAM also filed a response with the ALJ on Monday, arguing that the allegations "fail on their face to suggest any improper contacts between SAM and the DEA," and therefore they "can and should be quickly dispensed with by this Tribunal."
The organization asserted that, statutorily, unlawful ex parte communications would need to have occurred after the Justice Department posted its notice of proposed rulemaking, which is not explicitly alleged in the original motion.
"Standing alone, that deficiency itself is sufficient to dismiss Movants' speculation about supposed improper contacts," it said.
SAM also cited media reports from outlets including Marijuana Moment and The Wall Street Journal, as well as social media posts from supporters of the rescheduling effort, that contained information about the process that had not yet been made publicly available. It argued that such reporting undermined the allegation that Sabet's communications were uniquely improper.
"In short, the Motion is a transparent effort to smear both SAM and the DEA in an attempt to eliminate from this proceeding one of the strongest voices opposing rescheduling of marijuana," SAM said. "The Tribunal should deny Movants' invitation to create a sideshow requiring SAM and its counsel to expend more time and funds defending against unfounded attacks and instead should permit SAM to focus on the merits of these proceedings."
After the motion was filed with DEA ALJ John Mulrooney, <a href="https://www.marijuanamoment.net/dea-judge-gives-agency-one-week-to-address-allegations-of-illegal-talks-with-marijuana-opponents-amid-rescheduling-process/">the judge invited both the agency</a> <a href="https://www.marijuanamoment.net/dea-judge-invites-prohibitionist-group-to-explain-allegedly-unlawful-talks-with-agency-amid-marijuana-rescheduling-review/">and SAM to respond</a>, calling the nature of the alleged illegal communications "serious."
This comes just weeks before an initial December 2 hearing before the ALJ on the government's proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).
In a historic first, it was Attorney General Merrick Garland—and not DEA's Milgram—who signed the proposed rule to reschedule cannabis. The original motion said that fact, as well as DEA's apparent indecision on the proposed rule, warranted a change in the hearing structure.
The judge, in turn, said that the prospect of removing an agency head from rulemaking that it is responsible for overseeing would likely, "and correctly," be deemed beyond the ALJ office's jurisdiction.
Last week, Mulrooney officially ruled on <a href="https://www.marijuanamoment.net/dea-judge-issues-order-approving-and-denying-witnesses-for-marijuana-rescheduling-hearing-and-laying-out-next-steps/">which of the agency's 25 selected witnesses for the hearing will be able to participate</a>, while laying out the procedure for the administrative process—including how pro- and anti-reform speakers will be able to cross-examine one another.
Separately, the judge last week <a href="https://www.marijuanamoment.net/researcher-asks-dea-judge-to-postpone-marijuana-rescheduling-hearing-until-after-trump-takes-over/">denied a request from a cannabis and psychedelics researcher</a> to postpone the upcoming rescheduling hearing over the agency's alleged "improper blocking" of witnesses, while arguing that the process should be halted at least until President-elect Donald Trump's administration comes into power so it can review the rulemaking.
Mulrooney also <a href="https://www.marijuanamoment.net/dea-judge-rejects-veterans-groups-petition-to-participate-in-marijuana-rescheduling-hearing/">rejected a veterans group's petition to participate in the rescheduling hearing</a>, which the organization called a "travesty of justice" that excludes key voices that would be affected by the potential policy change.
For what it's worth, Vice President Kamala Harris said recently that part of the reason for the delay in the administration's marijuana rescheduling effort is&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-blames-marijuana-rescheduling-delay-on-dea-bureaucracy-while-defending-her-own-prosecutorial-record/">federal bureaucracy that "slows things down," including at DEA.</a>
In March, Harris also expressed some frustration with the bureaucratic process of rescheduling marijuana, prior to DOJ's formal recommendation,&nbsp;<a href="https://www.marijuanamoment.net/watch-live-vp-harris-talks-marijuana-ahead-of-white-house-meeting-with-cannabis-pardon-recipients/">calling on DEA to expediently finish the job</a>.
While the Biden–Harris administration facilitated the review that led to the DOJ rescheduling proposal, Trump has also voiced support for the reform.
In Congress, numerous lawmakers have shared their own perspectives on the proposed reform with DEA and DOJ since the Schedule III announcement was made.
In August, for example, Sen. Chuck Grassley (R-IA)&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-demands-answers-on-rush-to-reschedule-marijuana-from-top-biden-administration-officials/">raised concerns about the Biden administration's justification</a>&nbsp;for recommending marijuana rescheduling, demanding answers to questions from federal agencies about how they arrived at that decision in what he described as a rushed and unconventional administrative process.
A week earlier, top Democratic senators—including&nbsp; Senate Majority Leader Chuck Schumer (D-NY)—sent a separate letter to DOJ's Garland and DEA's Milgram urging the agencies to&nbsp;<a href="https://www.marijuanamoment.net/schumer-booker-and-other-senators-push-dea-to-promptly-finalize-marijuana-rescheduling/">"promptly finalize" the rule to reschedule marijuana</a>.
While rescheduling would remove certain research barriers and free up state-licensed cannabis business to take federal tax deductions under the Internal Revenue Service (IRS) code known as 280E, it would not federally legalize marijuana, as the&nbsp;<a href="https://www.marijuanamoment.net/marijuana-businesses-could-advertise-in-newspapers-and-magazines-if-rescheduling-is-approved-congressional-researchers-say/">Congressional Research Service (CRS) has made known in multiple recent reports</a>.
Meanwhile, two additional congressional lawmakers have joined the ranks of GOP members who are challenging what they say is&nbsp;<a href="https://www.marijuanamoment.net/gop-lawmakers-demand-answers-from-biden-administration-about-unusual-marijuana-review-process-behind-rescheduling-push/">the "unusual" process that led the Biden administration to propose rescheduling marijuana</a>, expressing concern about how the review was carried out and demanding answers.
Rep. Doug LaMalfa (R-CA)&nbsp;<a href="https://www.marijuanamoment.net/gop-congressman-says-marijuana-rescheduling-and-banking-reform-would-prop-up-an-immoral-industry/">condemned the Biden administration's push to reclassify marijuana</a>, as well as legislative efforts to enact bipartisan cannabis banking reform, because he says the policy changes would "prop up this immoral industry" and give a "green light to the evil that comes from drug use."
Sen. Bill Cassidy (R-LA) also blasted the Biden administration over what he described as&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-condemns-lack-of-transparency-in-marijuana-rescheduling-process/">repeated refusals from federal agencies to brief Congress</a>&nbsp;on its plans and justification for rescheduling marijuana, which he argues fuels speculation that the proposed policy change is politically motivated.
Similarly, 25 GOP congressional lawmakers sent a public comment letter in July opposing the administration's planned rescheduling of marijuana, specifically alleging&nbsp;<a href="https://www.marijuanamoment.net/gop-lawmakers-push-justice-department-to-reverse-course-on-marijuana-rescheduling/">the government's recommendation was based on politics rather than science</a>.

AKAN

CRON

FLGC

GRWG

IMCC

LFLY

MAPS

MSOS

SNDL

TLRY

Tom Angell Says "DEA says it is in the process of preparing public access to the cannabis rescheduling proceedings docket. For now, read Marijuana Moment's coverage of the latest significant filings:", 'DEA And Anti-Marijuana Group Deny Allegations They Conspired During Rescheduling Process' - Marijuana Moment

As the world hurtles toward an electrified future, the copper market <a href="https://www.benzinga.com/topic/copper">stands at a crossroads</a>. 
Insights from JPMorgan analysts Patrick Jones, Greg Shearer and Bill Peterson paint a complex picture: short-term hurdles for copper prices, but a glittering long-term outlook driven by electric vehicles and evolving supply dynamics.
This could seem as good news for those invested in United States Copper Index Fund ETV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPER#NYSE">CPER</a>), Global X Copper Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>), iShares Copper and Metals Mining ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICOP#NASDAQ">ICOP</a>) for the long-term.
<h2 class="wp-block-heading">EV Boom: Supercharging Copper Demand</h2>
The electric vehicle revolution is set to electrify copper demand. JPMorgan predicts copper usage in EVs will more than double from 1.4 million metric tons in 2023 to 3 million by 2030. While some worry that technological advances like thinner copper anode foils could dampen demand, the analysts argue otherwise. 
Larger EV sizes and a pivot toward lithium-iron-phosphate (LFP) batteries — which are more copper-intensive — are expected to drive long-term growth.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41337566/trump-2-0-trade-policies-could-hit-copper-stocks-harder-warns-jpmorgan-analyst">Trump 2.0 Trade Policies Could Hit Copper Stocks Harder, Warns JPMorgan Analyst</a>
<h2 class="wp-block-heading">New Technologies: Leaching A Lifeline?</h2>
Leaching technologies are generating buzz, but can they revolutionize copper supply? Not yet, say the analysts. While projects from major miners like Freeport-McMoRan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) and BHP Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) are on the horizon, these advancements are unlikely to offset supply declines before 2030.
At best, leaching could add 550,000 metric tons annually, just 2% of global supply.
<h2 class="wp-block-heading">Scrap &amp; Recycling: The Unsung Hero?</h2>
Recycling is a crucial cog in the copper machine, accounting for about 17% of refined supply in 2024, up from 14% in 2020. JPMorgan forecasts scrap supply will grow by 5-6% annually, faster than historical rates, yet insufficient to bridge the long-term deficit. Recycling alone won't solve copper's supply crunch.
<h2 class="wp-block-heading">Near-Term Risks, Long-Term Rewards</h2>
JPMorgan warns of near-term risks from macroeconomic pressures, particularly a potential devaluation of the Chinese yuan to 7.8 to 8.0 per U.S. dollar. This could lead to a 12-15% dip in copper prices, presenting headwinds for equities. However, the analysts remain bullish on the long-term trajectory, underpinned by a looming supply-demand gap.
Their picks? 
Lundin Mining Corp (OTCPK: LUNMF) leads in EMEA, while Teck Resources Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) tops the Americas. Asia-Pacific favorites include Zijin Mining and Merdeka Copper, with caution advised on Jiangxi Copper and Sandfire Resources.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41877899/trump-re-election-jolts-metals-market-as-gold-sees-a-stumble-not-a-sea-change">Trump Re-Election Jolts Metals Market As Gold Sees A &#8216;Stumble, Not A Sea Change&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Specialty ETFs

Commodities

Markets

ETFs

COPX

CPER

ICOP

LUNMF

TECK

Copper's High-Wire Act: Can EVs, New Tech Power The Metal's Next Big Surge?

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has risen 6.38% since its last report. The company recently reported that it has 259 thousand shares sold short, which is 2.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 8.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Chemed?

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 8.33% since its last report. The company recently reported that it has 6.62 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(LLY) - Analyzing Eli Lilly's Short Interest

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VRTX

Looking Into Vertex Pharmaceuticals's Recent Short Interest

Rumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced that streamer Dr. Disrespect will provide exclusive content to Rumble Premium and lead <a href="https://www.benzinga.com/pressreleases/24/11/g42162724/dr-disrespect-will-lead-rumble-gaming-join-rumble-premium">Rumble Gaming as an advisor</a>.
What Happened: Rumble announced Monday morning that Dr. Disrespect will begin streaming his content on the Rumble platform as part of an agreement that includes equity with milestones as a majority of its compensation.
Dr. Disrespect is set to provide exclusive content to Rumble Premium for his &#8220;Champions Club&#8221; community and lead Rumble Gaming, acting as an advisor and helping build the Rumble Gaming community.
Dr. Disrespect will make his Rumble debut on Dec. 2. Rumble will be offering a $10 discount for new subscribers to his community as part of the launch. 
&#8220;Rumble is in a new era, and I&#8217;m laser-focused on expanding into two categories: gaming and crypto. Dr Disrespect will give a much-needed injection into our gaming category,&#8221; said Chris Pavlovski, chairman and CEO of Rumble.
See Also: <a href="https://www.benzinga.com/markets/24/11/42158373/trumps-commerce-secretary-pick-howard-lutnicks-fund-owns-1-19b-in-nvidia-804m-in-tesla-here-is-a-look-at-his-portfolio">Trump&#8217;s Commerce Secretary Pick Howard Lutnick&#8217;s Fund Owns $1.19B In Nvidia, $804M In Tesla: Here Is A Look At His Portfolio</a>
<h3 class="wp-block-heading">How To Buy RUM Stock</h3>
By now you're likely curious about how to participate in the market for Rumble &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. 
In the case of Rumble, which is trading at $7.23 as of publishing time, $100 would buy you 13.83 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RUM Price Action: <a href="http://benzinga.com/quote/rum">Rumble shares</a> were up 13.3% at $7.35 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

Why Rumble Stock Is Rising Monday: 'Laser-Focused' On Gaming, Crypto Expansion

FANG

TRGP

Shares of oil and gas companies are trading lower following reports suggesting an Israel-Hezbollah ceasefire.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is heading higher on Wednesday alongside heavy pre-market trading of the coffee machine company&rsquo;s shares.



This has more than 8 million shares of NUZE stock changing hands as of this writing. That&rsquo;s well above its daily average trading volume of about 575,000 shares. Investors will also keep in mind that its <a href="https://finance.yahoo.com/quote/NUZE/key-statistics/">float is 560,520 shares</a>.



All of this activity comes without any clear news from Nuzee. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage that would cause NUZE stock to rally today.



One thing investors will note is that NUZE is a penny stock. That comes from its prior closing price of $1.03 per share and its market capitalization of just $2.459 million.



<h2>Why That Matters to NUZE Stock</h2>



Being a penny stock comes with the risk of extra volatility. That makes sense as retail and day traders sometimes pump up these shares.



However, that also means the stock isn&rsquo;t likely to maintain its increased price. Once those traders sell their shares for profits, NUZE is likely to come back down from this high. Traders will want to weigh that potential when considering a stake in Nuzee.



NUZE stock is up 133% as of Wednesday morning.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news ready to go on Wednesday! Among that is what has shares of Dermata Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/dear-sofi-stock-fans-mark-your-calendars-for-july-30-2/">Dear SOFI Stock Fans, Mark Your Calendars for July 30</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">Why Is Nuzee (NUZE) Stock Up 133% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Nuzee (NUZE) Stock Up 133% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

VSee Health, Dermata Therapeutics, and Exicure, Inc. are the 3 Penny Stocks to watch on August 6, based on&nbsp;TipRanks' Penny Stock Screener tool...

3 Penny Stocks to Watch Now, 8/6/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) just reported results for the second quarter of 2024.<ul><li>Dermata Therapeutics reported earnings per share of -$4.18. This was below the analyst estimate for EPS of -$3.79.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/drma-stock-earnings-dermata-therapeutics-for-q2-of-2024/">DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

Dermata Therapeutics GAAP EPS of -$4.18

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
What do you call a growth stock that isn&rsquo;t growing any more?



The answers are many. You can call it a disappointment. A drain on your portfolio. A bad investment. Any of these are true of F-rated <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a>, as evaluated by the Portfolio Grader.



And in today&rsquo;s market, you can ill-afford to a bad investment. The market is in some turmoil this summer.



I know it&rsquo;s only temporary, but times like these are when some investors start to panic and make bad decisions &ndash; particularly when they see their hard-earned money start to drain away in a sell-off.



It can be tempting to take a flyer on a stock in a weakened position. In fact, sometimes that can be a very good decision to buy strong growth stocks at a discount. 



You also need to be able to identify those opportunities rather than F-rated growth stocks that have little, if any, hope of bouncing back in the near future.



F-rated growth stocks are typically characterized by weak fundamentals, poor financial health, and inconsistent performance, which can lead to substantial losses. 



They can also be volatile, with extreme price fluctuations driven by speculation rather than solid financial performance.



We&rsquo;re using the Portfolio Grader today to help us identify the worst growth stocks available today, based on factors such as analyst sentiment, growth history, earnings reports and momentum. All of these names are on my list of stocks to avoid today.



<h2>Nio (NIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/nio1600-2-300x169.png" alt="NIO logo, sign atop of North American headquarters and global software development center in Silicon Valley. NIO is Chinese electric autonomous vehicles manufacturer"><div>Source: Michael Vi / Shutterstock.com</div></div>Chinese EV maker&nbsp;Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>) has to be one of the most disappointing electric vehicle stocks. I had high hopes at one point that Nio&rsquo;s battery-swapping technology would be a difference-maker and would allow Nio to become a dominant EV company in Asia.



But not any longer. It&rsquo;s hard to have faith in any company that used to trade for $60 a share and now is down closer to $3.



Nio has had a lot of starts and stops. It&rsquo;s getting ready to launch its new mass market EV brand, Onvo, with the first Onvo model, the L60, to debut in September. 



There&rsquo;s also a lot of competition in the Chinese EV space, and Nio will likely be shut out by cars that are selling at a lower price point than the L60, which has a pre-order price of $30,460.



Nio reported delivering 20,498 vehicles in July, which is the third consecutive month that the company delivered more than 20,000 vehicles. But the market is obviously not impressed, as NIO stock is down 60% this year and 33% in the last three months.



Nio gets a &ldquo;D&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>FuelCell Energy (FCEL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/fcel1600-1-300x169.png" alt="Person holding cellphone with logo of US fuel cell company FuelCell Energy Inc. (FCEL) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>FuelCell Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcel-stock-quote/">FCEL</a>) manufactures, operates and services Direct Fuel Cell power plants that produce hydrogen. For providers who are looking for a green energy solution, hydrogen is appealing because it produces zero carbon emissions.



It has the potential to be highly efficient in fuel cells by providing more energy per unit of fuel compared to traditional combustion engines.



The company has more than 100 fuel cell plants in operation around the world and has generated more than 15.8 million megawatt-hours of power.



But just because it sounds like a good idea doesn&rsquo;t make something a good investment. Second-quarter revenue was $22.4 million, down from $38.3 million a year ago. FuelCell Energy posted a loss of $7.1 million, or 7 cents per share.



Obviously, growth is not in the cards for FuelCell, despite its efforts to expand its business in the Koren market. There are much better opportunities for investors.



FCEL stock is down 71% so far this year. It gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>Tell me if you&rsquo;ve heard this one before &ndash; Mullen Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/">MULN</a>) stock is below $1 per share again.



This is a sad repeat of a story that&rsquo;s plagued the EV company for the last several months. Mullen actually enacted three reverse stock splits last year, including a 1-for-100 split in December, in a desperate ploy to keep the stock price over $1 and maintain compliance with Nasdaq listing rules.



The cumulative ratio of all these stock splits are 1-for 22,500. And more dilution is on the way, as Mullen announced plans to resell up to <a href="https://www.sec.gov/Archives/edgar/data/1499961/000182912624005041/mullenautomotive_s1.htm#a_004">85 million shares</a> on the conversion of notes and exercise of warrants. 



When Mullen made the announcement there were only 24.85 million shares outstanding. Mullen acknowledged that the transactions could lead to &ldquo;substantial diminution to the value of shares of common stock held by our current stockholders.&rdquo;



Mullen only invoiced for 362 vehicles in six months ending March 31. It posted a net loss of $235 million in that period, while invoicing only $16.3 million.



Mullen stock is trying to make deals to turn things around, but another reverse stock split seems inevitable. MULN stock is down 95% this year and earns a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>SolarEdge Technologies (SEDG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/sedg-stock-1-300x169.jpg" alt="SolarEdge logo on phone with American flag background. SEDG stock"><div>Source: IgorGolovniov / Shutterstock.com</div></div>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) is another green power company. It makes power optimizers and inverters to help solar panels operate more efficiently.



The primary issue for SolarEdge, however, isn&rsquo;t the quality of its work or the efficiency of its equipment. It&rsquo;s the overall economy that makes solar power investment less appealing right now.



Interest rates remain inflated and the Fed seems stubbornly opposed to providing relief. Solar panels are a significant expense and fewer people are willing to borrow money to convert their homes to solar as long as interest rates remain high.



<a href="https://investors.solaredge.com/static-files/ab9d304f-bfed-4320-95b0-bc5bdee6d0b2">Revenue in the second quarter</a> was $265.4 million, down 73% from a year ago. The company posted a net loss of $130.8 million, a year after posting a profit of $119.5 million.



If interest rates drop, then SolarEdge may return to its growth ways. But that&rsquo;s not happening now. SEDG stock is down 75% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>2U (TWOU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/twou1600-300x169.png" alt="Person holding smartphone with logo of American educational technology company 2U Inc. on screen in front of web page. Focus on phone display. Unmodified photo. TWOU stock"><div>Source: T. Schneider / Shutterstock.com</div></div>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) is an educational technology company that works with nonprofit colleges and universities to create online degree and nondegree programs. But it hasn&rsquo;t been a great business model, as many colleges are able to offer online courses without outside help.



The Maryland-based company filed for Chapter 11 bankruptcy in July, after reporting more than $1 billion in debt in the first quarter and only $125 million in cash. 



2U announced a deal with&nbsp;<a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">lenders to cut its debt by 50%</a>, while extending the duration of its loan. It will also receive an additional $110 million in capital from lenders.



TWOU stock is down 95% this year and is approaching $1 per share despite instituting a 1-for-30 reverse stock split this summer. The stock is one to avoid.



TWOU gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>Dermata Therapeutics (DRMA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) is a clinical-stage biotechnology company based in California. Dermata is focused on creating treatments for skin conditions and diseases.



Its lead drug candidate, DMT310, is in Phase 3 trials for the treatment of acne, rosacea, and psoriasis. It is a once-weekly topical product made from naturally sourced freshwater sponges. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis.



The company says it&rsquo;s enrolled more than 50% of its patients in the trial and hopes to complete enrollment in the second half the year.



The challenge with biotech companies, of course, is that research and development is expensive and companies don&rsquo;t have a revenue stream during the long testing process. Companies are reliant on raising money and acquiring partners during the testing until they can bring a drug to market and start gaining revenue.



For the second quarter, Demata reported having $4.9 million in cash on hand, down from $7.4 million in the previous quarter. The company spent $4.8 million during the quarter on research and company operations, and raised $2.3 million from selling warrants.



The company believes it has sufficient funds to operate into the fourth quarter, so it will have to raise additional money if its going to continue its work.



DRMA stock is down 75% this year and gets a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/plug1600-9-300x169.png" alt="Mobile phone with logo of American hydrogen fuel cell company Plug Power Inc. in front of business website. Focus on center of phone display. Unmodified photo. PLUG stock"><div>Source: T. Schneider / Shutterstock.com</div></div>Plug Power&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/plug-stock-quote/">PLUG</a>) had another bad day this week, as the company posted another disappointing earnings report that missed analysts&rsquo; expectations for both revenue and earnings per share.



The company, which is attempting to build the first commercially viable market for hydrogen fuel cell technology, posted revenue of $143.3 million for the second quarter, down from $260.1 million a year ago. 



The company also posted another <a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Power-Announces-Key-Developments-and-Strategic-Milestones-in-Second-Quarter-2024/default.aspx">big operating loss</a> of $244.6 million slightly worse than the $233.8 million loss that Plug sustained in the second quarter of 2023. Overall, Plug&rsquo;s loss came in at 36 cents per share. 



Even though Plug has deployed more than 69,000 fuel cell systems and more than 250 fueling stations, I wouldn&rsquo;t call what its doing a viable business. At some point you need to start making money, and Plug isn&rsquo;t anywhere close.



Plug is projecting full-year revenue this year to be between $825 million and $925 million. A year ago it posted revenue of $891 million, so it appears growth this year will be challenging at best.



PLUG stock is down 54% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/08/7-f-rated-growth-stocks-to-avoid-like-the-plague-in-august-2024/">7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024

Dermata Therapeutics prices $3.5M equity offering

Dermata Therapeutics files to sell 5.87M shares of common stock for holders

Dermata Therapeutics GAAP EPS of -$2.04 misses by $0.68

Dermata Therapeutics GAAP EPS of -$2.04

BLMZ

CERO

DRMA

DRMAW

DTCK

FCEL

HOTH

INDV

IROQ

MULN

NUZE

PLUG

SEDG

SLNA

TIVC

TWOU

VKTX

VSEE

VSME

XCUR

Offerings

Press Releases

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Biotech

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Events

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Comments

Dermata Therapeutics

Vendite allo scoperto

Dermata Therapeutics (NASDAQ:DRMA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO